Direct‐acting antivirals combination for elderly patients with chronic hepatitis C: A cost‐effectiveness analysis
Ciaccio A, Cortesi PA, Bellelli G, Rota M, Conti S, Okolicsanyi S, Rota M, Cesana G, Mantovani LG, Annoni G, Strazzabosco M. Direct‐acting antivirals combination for elderly patients with chronic hepatitis C: A cost‐effectiveness analysis. Liver International 2017, 37: 982-994. PMID: 27943549, DOI: 10.1111/liv.13339.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overAntiviral AgentsComputer SimulationCost-Benefit AnalysisDecision Support TechniquesDisease ProgressionDrug CostsDrug Therapy, CombinationFemaleFrail ElderlyGeriatric AssessmentHepatitis C, ChronicHumansLiver CirrhosisMaleMarkov ChainsModels, EconomicQuality-Adjusted Life YearsRisk FactorsTime FactorsTreatment OutcomeConceptsIncremental cost-effectiveness ratioChronic hepatitis CQuality-adjusted life yearsCost-effectiveness ratioElderly patientsCHC patientsHepatitis CFrailty phenotypeFrailty statusFibrosis stageLife yearsElderly CHC patientsMild fibrosis stageInterferon-free treatmentHealthcare system perspectiveLifetime time horizonCost-effectiveness analysisDAA treatmentDAA combinationsAdvanced fibrosisFrail subjectsClinical variablesLiver fibrosisF2 patientsAge 75